Gene by Gene's Clinical, Research Arrays Exempt from New Myriad BRCA Testing Agreement | GenomeWeb

Gene by Gene can still the return mutation status of the BRCA1 and BRCA2 genes to US and Canadian customers via its clinical and research-focused microarrays, despite a new agreement with Myriad Genetics that prohibits Gene by Gene from offering its BRCA single-gene and gene panel sequencing service within North America.

Houston-based Gene by Gene also recently received its College of American Pathologists accreditation for its laboratory, removing an obstacle to expanding its clinical testing services in the US.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.